SEC Comment Letter 0000000000-25-001913 to Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: Feb. 19, 2025 · CIK: 0002022416 · Accession: 0000000000-25-001913
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284873
Letter
February 19, 2025 Ilan Hadar Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Re:Silexion Therapeutics Corp Registration Statement on Form S-1 Filed February 12, 2025 File No. 333-284873 Dear Ilan Hadar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel, Esq.
Show Raw Text
February 19, 2025
Ilan Hadar
Chief Executive Officer
Silexion Therapeutics Corp
12 Abba Hillel Road
Ramat Gan, Israel 5250606
Re:Silexion Therapeutics Corp
Registration Statement on Form S-1
Filed February 12, 2025
File No. 333-284873
Dear Ilan Hadar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.